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Summary  
Background 
Previously published UK reports showed that 
excessively large doses of benzodiazepines and 
opiates were being commonly used to sedate 
elderly patients for gastrointestinal (GI) 
endoscopy.  This unsafe practice has lead to 
avoidable morbidity and mortality.  We have 
taken the opportunity provided by recent reports 
to examine whether GI endoscopy sedation 
practice in the elderly has improved in the light 
of this evidence and the publication of guidelines 
in which specific recommendations on sedation 
dosage are given.  
Methods 
Using data mining techniques, we have extracted 
data on the use of benzodiazepines and opiates 
from a recent NCEPOD report on deaths 
following GI therapeutic endoscopy and from 
unpublished data from six East Anglian hospital 
GI endoscopy databases.  We have compared 
and contrasted these data with re-analysed data 
from two previously published large audits of 
upper and lower GI endoscopy carried out in 
1991 and 1998 respectively. 
Findings 
Midazolam has largely replaced diazepam as the 
benzodiazepine of first choice and many more 
procedures are now carried out without sedation.  
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Improvements have occurred in the use of pulse 
oximetry, supplemental oxygen and continuous 
intravenous access.  Mean doses of 
benzodiazepines and opiates given for GI 
endoscopy sedation in the elderly still exceed 
published guidelines, although doses have fallen 
significantly since the 1990’s.  The use of 
flumazenil, a specific benzodiazepine antagonist, 
appears to be a good marker of over-sedation and 
cardiopulmonary complications were more 
common in patients who were given the drug.  In 
the NCEPOD study of patients who died within 
30 days after therapeutic endoscopy, the time 
between endoscopy and death was significantly 
shorter in those who received flumazenil.  In the 
East Anglian study, there was a two-fold difference 
in the average doses of both midazolam and 
pethidine used by individual endoscopists in elderly 
patients.  Despite the well-known synergism 
between opioids and benzodiazepines, worryingly, 
those endoscopists who used the highest average 
doses of midazolam in elderly patients also tended 
to be those who administered the largest amounts 
of pethidine. 
Interpretation 
Patient safety would be significantly improved if 
those GI endoscopists who regularly give 
unnecessarily high doses of sedative and analgesic 
drugs to elderly patients changed their sedation 
practice to conform to published guidelines.  
Regular audit of sedation dosages and reporting of 
‘near misses’ (including flumazenil usage), is 
recommended. 
Introduction 
It was well established over 25 years ago that 
elderly patients are particularly sensitive to the 
CNS depressant effects of oral benzodiazepines 
such as diazepam[1], chlordiazepoxide[1], 
flurazepam[2] and nitrazepam[3].  Although 
pharmacokinetic differences are undoubtedly 
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contributory[4], the evidence suggests that 
pharmacodynamic factors are much more 
important[5] when explaining the marked 
differences in benzodiazepine CNS sensitivity 
between the young and old.  Based on these and 
other studies[1-5], it has been standard clinical 
practice in the elderly to prescribe half (or less) of 
the dose of hypnotics such as nitrazepam and 
flurazepam that would normally be prescribed to 
younger patients. 
 
Midazolam has gradually replaced diazepam as 
the IV sedative of choice for most 
gastrointestinal (GI) endoscopic procedures[6, 7].  
As with orally administered benzodiazepines[1-3, 5], 
intravenous (IV) midazolam dosage needs to be 
reduced dramatically in the elderly[8], especially if 
a bolus technique is employed[9].  IV midazolam 
and diazepam can both depress respiration and 
cause marked hypoxia[10, 11]: hence the need for 
pulse oximetry, supplemental oxygen[12, 13] and the 
ready availability of the benzodiazepine 
antagonist, flumazenil[13, 14].  
 
Monitoring and safety guidelines for sedating 
patients have been issued in the past[13, 15, 16]; 
particularly in light of a 1991 UK audit of over 
14,000 patients undergoing an upper GI 
endoscopy[17].  The 1991 audit, published in 1995, 
found that over 100 patients died within 30 days 
of the procedure.  Several of these patients died 
as a result of being given too large a dose of 
either IV midazolam or diazepam[17].  Similar 
cases of sedation-related deaths have been 
reported elsewhere[18, 19].  
 
Previous guidelines[13, 15, 16] have all stressed the 
importance of not exceeding the dose of IV 
benzodiazepine recommended by the 
manufacturer and of reducing the dose 
sufficiently in elderly, frail or at-risk patients. 
 
More recent audits of endoscopic procedures 
such as colonoscopy[20] and Endoscopic 
Retrograde Cholangiopancreatography (ERCP)[21] 
have shown improved use of pulse oximeters, 
supplemental oxygen and indwelling IV cannulae 
when compared with the earlier report of Quine 
et al[17].  Despite this, and a small reduction in the 
mean doses of sedative and analgesic drugs being 
employed in the more recent audits[20, 21], there have 
been, once again, a number of reported sedation-
related cardiopulmonary deaths in elderly patients.  
A 2004 report by the National Confidential 
Enquiry into Patient Outcome and Death 
(NCEPOD), “Scoping our Practice”[22], found that 
there had been 1,818 deaths after therapeutic GI 
endoscopic procedures.  NCEPOD advisors 
judged that the sedation given was inappropriate in 
14% of cases, usually because an overdose of 
benzodiazepine had been administered. 
 
We decided to re-analyse the NCEPOD 
therapeutic endoscopy data in terms of sedation 
practice and to compare and contrast the results 
with 
 
a) the 1991 Upper GI Audit 
b) the 1998 Colonoscopy Audit 
c) a current six hospital East Anglian Study[23]. 
 
Our results show that many endoscopists are 
persisting in using unnecessarily large doses of IV 
sedative and analgesic drugs in elderly patients with 
potentially fatal consequences.  We make 
recommendations regarding drug dosage and 
clinical practice based on these findings. 
Patients, Materials and Methods 
NCEPOD Therapeutic Endoscopy Report 
This report studied 1,818 patients who died in 
hospital within 30 days of having undergone a 
therapeutic endoscopic procedure in England, 
Wales, Northern Ireland, Guernsey, the Isle of 
Man, the Defence Secondary Care Agency and 
hospitals within the independent sector.  Data was 
requested for the period of one year from 1st April 
2002 to 31st March 2003.  These procedures 
included oesophageal dilatation, oesophageal stent 
insertion, injection of oesophageal varices, 
Percutaneous Endoscopic Gastrostomy (PEG), 
ERCP and a number of lower GI therapies such as 
polypectomy and colonic stenting.  As described in 
detail in the report[22], the 1,818 patients who died 
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probably represents about 3 % of the total 
number of patients undergoing a therapeutic 
endoscopic procedure during the time of 
observation.  The anonymised database of the 
original report from NCEPOD was re-analysed 
by the medical data-mining group from the 
School of Computing Sciences at the University 
of East Anglia (UEA). 
Upper GI Endoscopy Audit 
In the four-month period from February to June 
1991 3,956 upper GI endoscopies were 
performed in the UK by the East Anglian Health 
Region, (an estimated 5.76 
gastroscopies/1000/year) and in the four-month 
period from April to August 1991, there were 
10,193 examinations carried out by the North 
West Health Region, (8.8/1000/year).  The total 
number of procedures performed was 14,149 of 
which 13,036 (92%), were diagnostic and the 
remaining 8% were therapeutic.  The audit 
included a 30-day post endoscopy period to study 
both morbidity and mortality.  The anonymised 
database used for the original report was 
provided for our use by the British Society of 
Gastroenterology (BSG).  
Colonoscopy Audit 
Over a four-month period in 1998, there were 
9,223 colonoscopies carried out in three Regions 
(North East Thames, East Anglia and West 
Midlands).  As in the upper GI audit, there was a 
30-day post colonoscopy period to study both 
morbidity and mortality.  The anonymised 
database used for the original report was again 
provided for our use by the BSG.   
East Anglian Endoscopy Database Study 
The Endoscopy Units of the following hospitals 
in East Anglia were included in the study: 
Norfolk and Norwich University Hospital, 
Cromer Hospital, Queen Elizabeth Hospital at 
King’s Lynn, North Cambridgeshire Hospital at 
Wisbech, the James Paget Hospital at Great 
Yarmouth and the Ipswich Hospital.  All these 
units used either Endoscribe or HCNscribe 
software as their Endoscopy reporting system 
and database.  With the permission of their IT, 
medical and nursing staff, a member of the medical 
data-mining group visited the hospital and took a 
copy of the Endoscribe/HCNscribe database. 
 
The databases from each of the hospitals were pre-
processed (correcting data errors, removing 
incomplete records and validating field entries).  
The hospitals and individual endoscopists were 
each given a code and the data was anonymised.  
The databases were transformed into a new data 
structure more suited to statistical analysis and data 
mining[24-26] and then combined into one database.  
Data from the Upper GI audit, the Colonoscopy 
audit and the NCEPOD audit were each processed 
in the same way to allow a truer comparison 
between the four studies. 
Statistical Analysis 
For each of the four above databases, we looked at 
the mean, median and 95% confidence limits 
around the doses of the different IV sedative and 
analgesic drugs used in the different patient age 
groups.  We also looked at the pattern of use of the 
benzodiazepine antagonist, flumazenil as a 
surrogate marker of a patient having inadvertently 
been given an excessive dose of either midazolam 
or diazepam.  Analysis was carried out using 
algorithms in SQL and PL-SQL, Oracle Data 
Miner and with the Arcus QuickStat statistical 
software[25]. 
Results 
NCEPOD Therapeutic Endoscopy Report 
This report studied 1,818 patients who died in 
hospital within 30 days of having undergone a 
therapeutic endoscopic procedure.  In 1,326/1,818, 
or 72.9% of cases, midazolam was used.  In 
1,294/1,326 or 97.6%, the actual dose of 
midazolam was recorded.  Flumazenil was 
prescribed in 160/1294 or 12.4% of patients given 
midazolam where the dosage was known and in 
5/32 or 15.6% of cases where the dose of 
midazolam was not recorded.  Diazepam was used 
in only 69/1,818 or 3.8% of cases.  Flumazenil was 
prescribed in 8/69 or 11.6% of patients given 
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diazepam.  In all but two of the cases having 
either midazolam or diazepam, the use of 
flumazenil was unplanned and the indication 
stated to be to reverse excessive sedation e.g. 
respiratory depression or loss of verbal contact. 
NCEPOD - Dose of Midazolam and 
Pethidine Used – with and without 
Flumazenil being required 
The mean age of the 160 patients given 
flumazenil (where the dose of midazolam was 
recorded) and the 1,134 who did not receive 
flumazenil was in both cases 78.4 years of age.  
As shown in Table 1, the mean dose of 
midazolam was significantly higher in the patients 
who received flumazenil (p=0.0034).  
Significantly more midazolam patients who 
required flumazenil also had the opioid pethidine 
(p<0.05) administered in a dose that was 
significantly higher (p=0.0074) than when 
reversal was not required. 
 
 Drug (mg) Flumazenil Used 
Flumazenil 
Not Used Significance 
Midazolam 4.3 (2.7) 3.7 (2.1) p=0.0034 
Pethidine 46.0 (14.6) 38.0 (13.9) p=0.0073 
 
Table 1.  Mean (SD) dose of midazolam and pethidine used in the 
NCEPOD study – with and without flumazenil being required. 
 
The mean dose of midazolam varied with the 
therapeutic GI procedure performed.  The mean 
dose of midazolam used for ERCP patients was, 
in all age groups, significantly greater (p<0.001) 
than either the therapeutic Upper or PEG group 
(see table 2).  Predictably therefore, flumazenil 
was required significantly more frequently to 
reverse the adverse effects of midazolam sedation 
during or following an ERCP than PEG insertion 
(p=0.0052) or either a GI therapeutic upper 
(p=0.0117) or lower (p=0.0034) endoscopic 
procedure (table 2). 
 
 ERCP PEG Upper GI Lower GI 
Mean (SD) 
Midazolam dose 5.1 (2.9) 3.3 (1.5) 3.9 (2.3) 3.2 (1.5) 
Significance vs. 
ERCP (Midazolam)  p<0.0001 p<0.0001 p<0.0001 
Number (%) given 
Flumazenil 
35/177 
(19.8) 
64/566 
(11.3) 
62/521 
(11.9) 
1/30 
(3.3) 
Significance vs. 
ERCP (Flumazenil)  p=0.0052 p=0.0117 p=0.0034 
 
Table 2.  Use of flumazenil in the NCEPOD study.  Flumazenil was 
used significantly more frequently during or after an ERCP than any 
other procedure. 
NCEPOD – Critical Incidents during the 
Endoscopic Procedure 
In all 93% (1,688/1,818) responded to the question 
relating to critical events.  Cardiorespiratory critical 
incidents during therapeutic endoscopy were 
relatively frequent.  In total, from 73 patients there 
were nine cardiac arrests, 7 respiratory arrests and 
62 reported incidents of clinically significant 
hypoxia.  If a cardiac arrest, respiratory arrest or 
hypoxic incident was reported then flumazenil was 
given in significantly more cases than when no 
such critical episode was reported: 27/73 or 37.0% 
vs. 125/1,615 or 7.7% (p<0.0001). 
NCEPOD – Time to Death after the 
Endoscopic Procedure and the Effect of 
Having Required Sedation Reversal with 
Flumazenil 
In the NCEPOD database, it was possible to 
calculate the time in days from the endoscopic 
procedure to death for 1,789 patients.  In this 
group, there were 173 patients who received 
flumazenil and 1,616 patients who did not.  Those 
given flumazenil died on average two days earlier 
than those not given the reversal agent (p<0.05).  
 
As shown above, the ERCP group received the 
largest doses of midazolam and had the highest 
percentage flumazenil usage.  When the ERCP 
group was considered separately, (see figure 1) the 
median time to death was on average four days 
earlier when flumazenil had been used than when it 
was not required (p=0.0108). 
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Figure 1.  A ‘box and whisker’ plot shows that patients undergoing 
an ERCP examination on average died 4 days earlier when 
flumazenil was required to reverse their midazolam sedation when 
compared with those whose sedation did not require reversal. 
NCEPOD – Effect of Endoscopist’s Previous 
Sedation Training on the Sedation Dose and 
use of Flumazenil 
In all, for 634 of the patients involved in the 
NCEPOD study, the endoscopist stated that they 
had had previous training in sedation techniques.  
While in 1,171 of the patients, the endoscopists 
conducting the examination indicated they had 
not received specific training in sedation.  There 
was no difference in either the dose of 
midazolam (means both 3.8 mg) or pethidine 
(mean dose of 36.2 mg and 39.2 mg respectively) 
in the sedation ‘trained’ and ‘untrained’ groups.  
Similarly, flumazenil requirements to reverse 
excessive sedation were very similar at 67/644 or 
10.4% and 109/1172 or 9.3% respectively in the 
2 groups.  Just how high the doses of midazolam 
administered were on occasion is illustrated in 
figure 2.  It can be seen that sedation training 
made no difference to the dose of drug 
administered to patients over the age of 90. 
 
 
 
Figure 2.  Each data point represents a single dose of midazolam 
administered by an individual endoscopist to a patient over the age of 90 
years.  It can be seen that those claiming to have had previous training in 
sedation techniques (red symbols) used no less sedation than those who 
had not been specifically trained (blue symbols). 
Upper GI Endoscopy Audit 
In East Anglia and the North West, 86% (3,405) 
and 84% (8,593) of upper GI endoscopies were 
performed with some form of intravenous sedation 
plus or minus local anaesthetic.  In all, midazolam 
was used in 52.5% of cases and diazepam (mainly 
in the form of Diazemuls) was given to 47.5% of 
patients.  At the time of this audit, diazepam was 
the preferred intravenous sedative in East Anglia 
(used in 59 % of all patients sedated) whereas in 
the North West Region more endoscopists 
favoured midazolam (57% of all patients sedated).  
 
The mean dose of diazepam used for sedation in 
the two regions was 13.5 mg, (East Anglia) and 
14.0 mg, (North West) and for midazolam, the 
mean dose was 5.7 mg in both regions.  The 
distribution of dosages used in both regions was 
equally wide; maximum doses of diazepam and 
midazolam used were 50 mg and 30 mg 
respectively.  The mean dose of both midazolam 
and diazepam given decreased with advancing age 
(see table 3), but for each age group the dose given 
to individual patients varied enormously. 
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Age 
Group 
Upper GI 
Audit 
Colon 
Audit NCEPOD 
East 
Anglian 
Under 20 6.7 (3.1) 8.0 (4.0)  4.9 (1.7) 
20-29 7.1 (3.1) 6.5 (3.7)  4.7 (1.5) 
30-39 6.7 (2.8) 6.3 (4.1)  4.7 (1.4) 
40-49 6.7 (2.7) 6.0 (3.2)  4.5 (1.4) 
50-59 6.0 (2.5) 5.8 (3.2) 4.0 (n=4) 4.4 (1.4) 
60-69 5.4 (2.1) 5.4 (3.0) 2.0 (n=2) 4.0 (1.3) 
70-79 4.6 (2.0) 4.9 (2.1) 4.8 (1.9) 3.5 (1.3) 
80-89 4.0 (1.9) 4.2 (1.9) 2.7 (0.9) 3.1 (1.2) 
90 plus 4.3 (2.4) 3.4 (1.4) 2.7 (0.6) 2.6 (1.0) 
 
Table 3.  Mean (SD) dose of midazolam used in patients of different 
age groups in the four different audits discussed in the present paper. 
Upper GI Endoscopy Audit - relationship 
between the dose of diazepam or Midazolam 
administered and the use of Flumazenil 
Flumazenil was used in 382/11,896 or 3.2% of all 
cases sedated with either midazolam or diazepam.  
Patients in the NW Region received flumazenil in 
4% of cases compared with 2% in East Anglia.  
This difference was almost entirely due to the 
fact that two centres in the NW (who contributed 
189 and 92 patients respectively) were at that 
time using flumazenil routinely in all patients 
being sedated with midazolam.  If these two 
centres are excluded, then 290/11,513 or 2.5% of 
sedated patients had flumazenil reversal. 
 
The mean dose of Diazemuls was 18.9 mg when 
flumazenil was also given compared 13.1 mg 
when it was not (p<0.0001).  Excluding the two 
units where Flumazenil was given routinely to all 
patients, the mean dose of Midazolam when 
Flumazenil was also given was 5.8 mg compared 
to 5.7 mg without (p=0.172) 
 
In 1991, many endoscopists in both Regions 
tended to use the same dose of diazepam or 
midazolam irrespective of patient age or ASA 
status.  We were thus able to look at the 
percentage of patients in different age groups 
receiving a) 10 mg of diazepam b) 20 mg of 
diazepam or c) 5 mg of midazolam (again 
excluding the two groups from the NW 
mentioned above) who subsequently were given 
flumazenil (see figure 3).  It can be seen that 
flumazenil use was both dose and age-related and 
increased dramatically after 70 years of age. 
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Figure 3.  Relationship between the age of patient and reported use of 
flumazenil when a 10 mg or 20 mg dose of diazemuls or a 5 mg dose of 
midazolam was given. 
1998 Colonoscopy Audit 
In this study in three Health Regions carried out 
over a four-month period in 1998, 73 Endoscopy 
units prospectively audited their colonoscopic 
practice plus 30-day morbidity and mortality 
figures.  In all 9,223 colonoscopies were 
performed.  In 94.6%, some form of sedation was 
used.  When sedation was used, midazolam was 
given in 88.6% of cases and diazepam (as 
Diazemuls) in 11.4%.  The most common was a 
combination of pethidine and midazolam (57.8% 
of colonoscopies).  The mode dose of midazolam 
was 5.0 mg (range 0.5 - 20 mg) while that of 
Diazemuls was 10 mg (range 1.0 - 30 mg).  The 
mode dose of pethidine was 50 mg (range 10 - 100 
mg).  The mean dose of midazolam was 5.8 mg 
while that of Diazemuls was 13.2 mg.  The mean 
dose of pethidine was 48.3 mg. 
Colonoscopy Audit - Relationship between the 
Dose of Midazolam given and Flumazenil use 
Flumazenil was used in 3.4% of patients.  In the 
vast majority of these cases, this was to reverse 
excessive benzodiazepine sedation[20].  Although 
there was a small reduction in the maximum 
sedation dosages used when compared with the 
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Quine audit[17], mean dosages for midazolam 
were very similar.  There were still many 
endoscopists using the same dose of midazolam 
(most often 5 mg) in all age groups.  We were 
thus able to look at the percentage of patients in 
different age groups receiving 5 mg of midazolam 
who subsequently required reversal with 
flumazenil (see figure 4).  It can be seen that, as 
in the Quine study (see figure 3), flumazenil 
usage increased markedly after the age of 70 years 
of age. 
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Figure 4.  Relationship between the age of patient and reported use of 
flumazenil when a 5mg dose of midazolam was administered.  The 
graph also shows comparable data from the East Anglian Study. 
East Anglian Endoscopy Database Study 
The number of Endoscopy reports collected 
from each hospital and the time-period over 
which the data was collected is given in table 4.  
In total, the combined database included 51,609 
upper GI endoscopies (of which 4,161 where 
therapeutic), 2,406 ERCPs, 1,061 PEGs and 
19,050 colonoscopies.  For upper GI endoscopy, 
the percentage of patients who had their 
procedure performed without any IV sedation 
was 20,138/ 51,609 or 39 %.  This figure is 
significantly greater (p<0.0001) than the figure of 
1,841/13,737 or 13.4% reported in the 1991 
OGD audit of Quine et al[17]. 
 
Hospital Number of Procedures Period Covered 
A 28 184 Feb 2002 – Sep 2004 
B 15 957 Mar 2001 – Jun 2004 
C 19 913 Jan 2000 – Feb 2005 
D 12 855 Jan 2000 – Aug 2005 
E 9 908 Jan 2000 – Aug 2005 
Total 86 817  
 
Table 4.  East Anglian study, Number of procedures and the period 
covered, by hospital. 
 
Fewer endoscopists were still using diazepam 
(mainly in the form of Diazemuls).  Only 8.9% of 
all sedated endoscopic procedures were carried out 
using diazepam.  These were mainly performed by 
just two endoscopists (who contributed 3,354 and 
982 cases respectively).  The mean (SD) dose of 
diazepam used in all patients was 9.3 (2.1) mg, 
while in the case of OGD and colonoscopy it was 
9.2 (2.4) mg and 9.4 (1.8) mg respectively.  These 
diazepam doses were significantly less than in the 
1991 upper GI and 1998 colonoscopy audits when 
the figures were 14.0 (11.0) mg and 13.2 (6.8) mg 
(p<0.0001 and p<0.0001 respectively).  In the case 
of the 91.1% of sedated patients who were sedated 
with midazolam, the mean (SD) dose of 
midazolam used in all patients was 3.9 (1.4) mg, 
while in the case of OGD and colonoscopy it was 
3.8 (1.4) mg and 3.9 (1.3) mg respectively.  These 
doses were significantly less than in the 1991 upper 
GI and 1998 colonoscopy audits[19], where the 
comparative figures were 5.6 (2.6) mg and 5.8  (3.1) 
mg (p<0.0001 and p< 0.0001 respectively).  
 
The mean doses of midazolam and pethidine used 
in the different age groups of patients in East 
Anglia for procedures such as PEG tube 
placement, ERCP, colonoscopy and therapeutic 
upper GI Endoscopy are shown in tables 5 to 9.  
For purposes of comparison, the same tables 
contain the data calculated from a) the Quine audit 
of OGD b) the Bowles colonoscopy audit and c) 
NCEPOD report. 
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 Table 5.  Mean (SD) dose of pethidine used in patients of different 
age groups in the four different audits discussed in the present paper. 
 
Mean (SD) Midazolam Mean (SD) Pethidine 
Age 
Group NCEPOD East Anglian NCEPOD 
East 
Anglian 
Under 20  8.5 (2.2)  55.6 (15.7) 
20-29  7.2 (2.6)  54.3 (12.7) 
30-39 12.5 (2.5) 7.2 (2.3) 50.0 (n=2) 56.5 (18.9) 
40-49  6.2 (2.1)  52.7 (12.9) 
50-5 7.4 (3.3) 5.9 (2.2) 41.7 (11.8) 52.6 (13.3) 
60-69 6.4 (4.0) 5.4 (1.8) 45.6 (9.6) 50.2 (10.9) 
70-79 5.3 (2.5) 4.8 (1.9) 41.9 (11.9) 47.9 (10.9) 
80-89 4.4 (2.0) 4.1 (1.4) 33.1 (16.2) 43.9 (11.1) 
90 plus 3.7 (1.8) 3.6 (1.2) 33.8 (13.8) 39.0 (12.5) 
 
Table 6.  Mean (SD) dose of midazolam and pethidine used in 
ERCP patients of different age groups in both the East Anglian 
study and the NCEPOD report. 
 
 
Age Group NCEPOD - PEG East Anglian - PEG 
Under 20  4.4 (3.0) 
20-29 3.5 (0.5) 3.9 (1.1) 
30-39 3.9 (0.9) 4.3 (1.3) 
40-49 4.3 (3.2) 5.0 (2.0) 
50-59 5.2 (1.8) 4.1 (1.6) 
60-69 3.5 (1.2) 3.8 (1.4) 
70-79 3.3 (1.4) 3.4 (1.3) 
80-89 3.0 (1.3) 2.9 (0.9) 
90 plus 2.9 (1.0) 2.4 (0.9) 
 
Table 7.  Mean (SD) dose of midazolam used in PEG patients of 
different age groups in both the East Anglian audit and the 
NCEPOD report. 
 
Age group NCEPOD East Anglian Colon Audit 
Under 20  5.0 (1.6) 8.0 (4.0) 
20-29  4.6 (1.5) 6.5 (3.7) 
30-39  4.5 (1.3) 6.3 (4.1) 
40-49  4.4 (1.3) 6.0 (3.2) 
50-59 4.0 (n=4) 4.2 (1.2) 5.8 (3.2) 
60-69 2.0 (n=2) 3.9 (1.2) 5.4 (3.0) 
70-79 4.8 (1.9) 3.5 (1.2) 4.9 (2.1) 
80-89 2.7 (0.9) 3.1 (1.2) 4.2 (1.9) 
90 plus 2.7 (0.6) 2.6 (0.8) 3.4 (1.4) 
 
Table 8.  Mean (SD) dose of midazolam used in colonoscopy in patients 
of different age groups in the East Anglian study, colonoscopy audits 
and the NCEPOD report. 
 
Age group NCEPOD East Anglian Colon Audit 
Under 20  46.3 (10.8) 52.4 (18.7) 
20-29  48.7 (9.7) 51.1 (12.6) 
30-39  48.1 (9.9) 50.2 (12.1) 
40-49  47.9 (10.5) 49.4 (12.1) 
50-59 50.0 (n=1) 46.3 (10.8) 48.9 (10.1) 
60-69 40.0 (n=1) 43.8 (11.4) 47.8 (9.8) 
70-79 41.7 (11.8) 40.5 (12.3) 46.1 (10.6) 
80-89 35.7 (12.4) 37.3 (12.6) 40.7 (12.5) 
90 plus 20.9 (5.9) 32.3 (11.2) 43.8 (10.8) 
 
Table 9.  Mean (SD) dose of pethidine used in colonoscopy in patients 
of different age groups in the East Anglian study, colonoscopy audits 
and the NCEPOD report. 
Age 
Group 
Upper GI 
Audit 
Colon 
Audit NCEPOD 
East 
Anglian 
< 20 50.0 (n=4) 52.4 (18.7)  45.5 (11.8) 
20-29 50.0 (13.8) 51.1 (12.6)  48.6 (10.2) 
30-39 60.6 (24.0) 50.2 (12.1)  48.4 (10.5) 
40-49 54.1 (24.6) 49.4 (12.1)  48.1 (10.8) 
50-59 47.5 (12.5) 48.9 (10.1) 50.0 (n=1) 46.6 (10.9) 
60-69 47.9 (13.1) 47.8 (9.8) 40.0 (n=1) 44.2 (11.6) 
70-79 46.2 (12.6) 46.1 (10.6) 41.7 (11.8) 40.9 (12.5) 
80-89 37.8 (14.9) 40.7 (12.5) 35.7 (12.4) 38.7 (12.6) 
90 plus 41.3 (13.4) 43.8 (10.8) 20.9 (5.9) 35.1 (12.3) 
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East Anglian Study - relationship between 
the dose of midazolam administered and the 
use of flumazenil 
In the 49,681/86,817 patients, who were sedated 
with midazolam for any procedure, the overall 
percentage recorded as subsequently being given 
flumazenil was 0.8%.  The figures for upper GI 
endoscopy, PEG insertion, ERCP and 
colonoscopy were 0.9%, 3.2%, 1.8% and 0.6% 
respectively.  In all patients given exactly 5mg of 
midazolam, the relationship between age and 
percentage recorded as having been given 
flumazenil is shown in figure 5. 
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Figure 5.  Relationship between the age of patient and reported use of 
flumazenil when a 5mg dose of midazolam was administered for any 
procedure. 
East Anglian Study – Individual 
endoscopist’s variation in average dose of 
midazolam and pethidine prescribed in 
patients over the age of 70 years 
We noted a 2.0 - 2.5 fold variation in the mean 
dose of both midazolam and pethidine being 
used by different individual endoscopists to 
sedate their elderly patients.  These differences 
were particularly marked in the case of patients 
undergoing colonoscopy.  Typical results from 
hospital A and B are shown in figures 6 and 7. 
 
 
 
Figure 6.  Shows a 2.5 fold variation in the dosage of midazolam that a 
patient over the age of 70 can expect to receive depending on which 
endoscopist administers the sedation.  Each data point represents the 
average dose of midazolam in mg given to patients over the age of 70 
years by different individual endoscopists in either hospital A (red 
symbols) or hospital B (blue symbols).  
 
 
 
Figure 7.  Shows a two-fold variation in the dosage of pethidine that a 
patient over the age of 70 can expect to receive depending on which 
endoscopist administers the sedation.  Each data point represents the 
average dose of pethidine in mg given to patients over the age of 70 years 
by different individual endoscopists in either hospital A (red symbols) or 
hospital B (blue symbols).  
 
In order to see if those colonoscopists who were 
using a relatively large average dose of midazolam 
were compensating by using a smaller dose of 
pethidine (or vice versa), we correlated each 
colonoscopists mean dose of midazolam with their 
mean dose of pethidine in the over 70 year old 
group.  As can be seen from the example data 
from one large hospital shown in figure 8, the 
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results showed just the opposite.  Those 
endoscopists using larger mean dosages of 
midazolam were also frequently the same 
endoscopists who administered relatively high 
doses of pethidine (p=0.0135). 
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Figure 8.  Hospital A - Shows the relationship between the mean 
midazolam dose and the mean pethidine dose given by individual 
endoscopists (who performed at least ten procedures) to patients over 
the age of 70 years of age. 
Discussion 
As the NPSA (National Patient Safety 
Association) points out, the medical profession is 
notoriously slow to learn from its mistakes and 
‘near misses’[27].  A new report from the National 
Audit Office(NAO) entitled ‘A safer place for 
patients: learning to improve patient safety’[28] 
accepts that there is significant under-reporting 
of deaths and serious incidents within the NHS. 
The NAO estimates that 22% of incidents, many 
of which are medication errors, still go 
unreported and agrees with the NPSA that ‘near 
misses’ are rarely acted upon[28]. 
NCEPOD Study 
Our results taken from the NCEPOD report 
clearly show that, if elderly patients are given an 
IV benzodiazepine in the sort of doses that are 
more appropriate for fit young adults, then their 
safety is endangered.  In the NCEPOD study, the 
benzodiazepine antagonist flumazenil was almost 
entirely given to attempt to reverse an overdose 
situation. In those patients who were given an IV 
dose of a benzodiazepine, midazolam was used in 
95% of cases while diazepam was employed in just 
5% of patients.  Detailed analysis therefore was 
concentrated on midazolam usage.  The mean dose 
of midazolam given when flumazenil was required 
was significantly higher than that when reversal 
was not needed.  Predictably, bearing in mind the 
well-known synergism between benzodiazepines 
and opioids[29], flumazenil was also required 
significantly more frequently when midazolam was 
combined with pethidine. 
 
Patients who needed to have their midazolam 
reversed were more likely to a) have a critical event 
such as significant hypoxia leading in certain cases 
to cardiopulmonary arrest during their endoscopy 
and b) die on average two days earlier than 
comparable patients not requiring flumazenil.  It 
was of interest that the patients undergoing an 
ERCP examination: 
 
i) had the largest doses of sedation 
ii) required flumazenil significantly more 
frequently that other groups 
iii) died, on average, four days earlier when 
reversal was required 
 
It has previously been shown that, as for oral 
benzodiazepines[1-5], elderly patients require only a 
fraction of the dose of midazolam needed by fit 
young adults[11].  Most endoscopists in the UK 
administering IV sedative plus or minus an 
analgesic drug use a bolus injection over a few 
seconds rather than the more correct slow titration 
method.  In this situation, even more dramatic 
reductions in dosage are required[9, 30]. 
 
The BSG, in its most recent guidelines on sedation 
and safety published in Sept 2003, made 
recommendations regarding dosage of midazolam 
and pethidine[16].  In the case of patients over the 
age of 70 years, the BSG suggests an average dose 
of no more than 2 mg of midazolam while in a fit 
young adult a dose of 5 mg might be more 
appropriate.  Should an opioid such as pethidine be 
required, as it frequently is for procedures such as 
ERCP or colonoscopy, then the BSG recommends 
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that the opioid be given first and then the 
benzodiazepine given slowly and cautiously[16].  In 
the case of pethidine, the BSG has suggested an 
average dose of no more than 25 mg in a patient 
over the age of 70 years of age and no more than 
50 mg for a fit young adult.  
Bearing in mind the fact that the mean age of 
patients in the NCEPOD Therapeutic 
Endoscopy study was 78.4 years and that some 
80% were classed as being ASA grade 3, the 
doses of midazolam and pethidine given to many 
patients (table 1 and figure 2) were clearly 
excessive. 
Upper GI Endoscopy and Colonoscopy 
Audits 
Comparing the two audits shows a significant 
improvement over time in terms of reduction in 
mean diazepam but not midazolam drug dosage.  
There was also a marked increase in the use of 
such measures as pulse oximeters, supplemental 
oxygen and indwelling IV cannulae.  The fact that 
the procedure related mortality, 1:2,000 for upper 
GI endoscopy and 1:1,500 for colonoscopy, was 
not improved was disappointing. 
 
Over 100 of the 14,000 patients in the upper GI 
audit died within 30 days of the procedure.  
While only seven cases were considered definitely 
procedure-related, it may be that many of the 
post procedure myocardial infarctions, cerebro-
vascular accidents and aspiration pneumonia 
cases were also causally related.  Of the 11 
pneumonias, 6 cerebro-vascular accidents and 19 
myocardial infarctions, 24/36, some two-thirds, 
of these complications occurred within seven 
days of the procedure.  Similarly, in the case of 
the colonoscopy audit, of the 10 deaths occurring 
within 30 days of the procedure, some six elderly 
patients died from cardio-pulmonary 
complications.  In several of these, excessive 
doses of sedation may again have had a part to 
play in the patient’s final demise. 
 
Revisiting the two databases has allowed us to 
examine the relationship between benzodiazepine 
dosage and CNS depression using flumazenil 
administration as a surrogate marker of increasing 
sensitivity to the drugs in the elderly.  The shape of 
the curves shown in figure 3 with a rapid rise in the 
incidence of side effects in the over 70 year old age 
group are remarkably similar to those reported by 
Greenblatt et al back in 1977[2].  As in that earlier 
study, we have shown that there are clear dose and 
age related effects associated with giving 
unnecessarily large doses of IV benzodiazepines to 
elderly patients.  
East Anglian Study 
Diazepam, in the form of diazemuls, is now only 
rarely employed by endoscopists in East Anglia 
with only 3.5% of endoscopists still regularly using 
it.  Unlike the situation in 1991, midazolam is now 
the preferred benzodiazepine by the overwhelming 
majority of endoscopists.  Many more patients are 
now asking to have their upper GI endoscopies 
performed without using any IV sedation than was 
the case 15 years ago.  Furthermore, as shown in 
tables 5 to 9, the doses of midazolam and 
pethidine currently in use are certainly significantly 
less than those used in 1991 or even 1998.  Many 
elderly patients having both diagnostic as well as 
therapeutic procedures, however, are still being 
given doses of sedative and analgesic drugs that are 
well in excess of BSG guidelines[16].  Since these 
doses are of similar size to those used in the 
NCEPOD study of 2002-03, the implication has to 
be that sedation-related cardiopulmonary 
complications remain more common than is 
generally recognised. 
 
The East Anglian study showed that the dose of 
either midazolam or pethidine that an individual 
patient is given still appears, in many cases, to 
depend as much on the endoscopist performing 
the procedure as either the age or ASA status of 
the patient.  As illustrated in figures 6 and 7, 
patients over the age of 70 are still regularly being 
given twice or more of the BSG recommended 
dosage of midazolam and pethidine.  Furthermore 
many endoscopists are either unaware of, or 
choose to ignore, the known synergism between 
benzodiazepines and opioids[29] and use excessive 
doses of both agents (see figure 8). 
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Flumazenil was used in 3.4% of patients in the 
upper GI audit, 3.5% of patients in the 
colonoscopy audit and 7% of patients in the 
most recent (and yet largely unpublished) ERCP 
audit[21].  All these percentages are considerably 
lower than the reported use of flumazenil in the 
NCEPOD study where the overall figure of 12% 
rose to almost 20% in the case of the ERCP 
group (table 2).  These differences might relate, 
in part, to the fact that so many of the patients in 
the NCEPOD study were on average more frail 
and elderly than those in the other audits. 
 
In the East Anglian study, the overall figure for 
flumazenil use was 0.8% of those sedated with 
midazolam.  This is almost certainly a gross 
underestimate of the true current use of 
flumazenil in UK endoscopy units, since any 
reversal that is carried out after the patient leaves 
the endoscopy unit (or is returned to the ward) 
would not normally be recorded on the 
endoscopy database.  The shape of the curve 
relating a 5 mg dose of midazolam to age and 
flumazenil use, however, is very similar, if much 
lower, than that generated from properly 
conducted prospective audits with 30-day 
morbidity and mortality data (see figures 4 and 5).  
Monitoring the use of flumazenil might be one 
way of prospectively looking at a hospital’s 
sedation practice, but in the case of an endoscopy 
unit, this would need to include collecting 
information on any doses given after leaving the 
unit as well as those given during or immediately 
after the procedure. 
Conclusions 
In patients as ill, frail and complicated as those in 
the NCEPOD therapeutic endoscopy study, it is 
always very difficult to decide how large a part 
the sedation-related cardio-pulmonary 
complications played in any individual patient’s 
final demise.  Based on our detailed study of both 
the NCEPOD report as well as other relevant 
databases discussed in the present paper, we can 
certainly conclude that elderly and/or frail 
patients’ lives and safety are still being put at risk 
unnecessarily, by the common practice of not 
reducing sedation/analgesia dosage sufficiently to 
allow for their advanced age and co-morbidity.  We 
strongly recommend that endoscopists adhere to 
the BSG 2003 guidelines on sedation dosage[16] and 
welcome the NPSA’s recent suggested changes to 
NHS sedation practice[31] which are, in part, a 
response to the finding of the present study. 
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